Which is the preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Full Text
Cardiovascular Diabetology,

Mallat SG – Clinical studies suggest that in CV high–risk patients and those with evidence of renal disease, the use of an ARB/CCB combination may be preferred to ARB/HCTZ combinations due to superior renoprotective and CV benefits and reduced metabolic side effects in patients with concomitant metabolic disorders. However, selection of the most appropriate antihypertensive combination should be dependent on careful review of the individual patient and appropriate consideration of drug pharmacology.

  • Hypertension is a major associated risk for organ damage and mortality, which is further heightened in patients with prior cardiovascular (CV) events, comorbid diabetes mellitus, microalbuminuria and renal impairment.
  • Given that most patients with hypertension require at least two antihypertensives to achieve blood pressure (BP) goals, identifying the most appropriate combination regimen based on individual risk factors and comorbidities is important for risk management.
  • Single–pill combinations (SPCs) containing two or more antihypertensive agents with complementary mechanisms of action offer potential advantages over free–drug combinations, including simplification of treatment regimens, convenience and reduced costs.
  • The improved adherence and convenience resulting from SPC use is recognised in updated hypertension guidelines.
  • Despite a wide choice of SPCs for hypertension treatment, clinical evidence from direct head–to–head comparisons to guide selection for individual patients is lacking.
  • However, in patients with evidence of renal disease or at greater risk of developing renal disease, such as those with diabetes mellitus, microalbuminuria and high–normal BP or overt hypertension, guidelines recommend renin–angiotensin system (RAS) blocker–based combination therapy due to superior renoprotective effects compared with other antihypertensive classes.
  • Furthermore, RAS inhibitors attenuate the oedema and renal hyperfiltration associated with calcium channel blocker (CCB) monotherapy, making them a good choice for combination therapy.
  • The occurrence of angiotensin–converting enzyme (ACE) inhibitor–induced cough supports the use of angiotensin II receptor blockers (ARBs) for RAS blockade rather than ACE inhibitors.
  • In this regard, ARB–based SPCs are available in combination with the diuretic, hydrochlorothiazide (HCTZ) or the calcium CCB, amlodipine.
  • Telmisartan, a long–acting ARB with preferential pharmacodynamic profile compared with several other ARBs, and the only ARB with an indication for the prevention of CV disease progression, is available in two SPC formulations, telmisartan/HCTZ and telmisartan/amlodipine.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Endocrinology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Endocrinology Articles

1 Association between sugar-sweetened beverages and type 2 diabetes: a meta-analysis Journal of Diabetes Investigation, November 13, 2014    Evidence Based Medicine    Review Article

2 Effects of 12 weeks high-dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency – A double-blind, randomized, placebo-controlled trial Metabolism, July 9, 2014    Clinical Article

3 Chemical in coffee may help prevent obesity-related disease University of Georgia Research News, November 18, 2014

4 Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: The LIBRA Trial Diabetes Care, September 26, 2014    Clinical Article

5 The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus Canadian Journal of Diabetes, October 28, 2014    Review Article

6 Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States Advances in Therapy, November 21, 2014    Clinical Article

7 Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin Diabetes Care, November 4, 2014    Clinical Article

8 Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis Diabetes Care, October 24, 2014    Clinical Article

9 Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy Endocrine Practice, November 7, 2014    Clinical Article

10 Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial Diabetic Medicine, November 12, 2014    Clinical Article

11 A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise Diabetes/Metabolism Research and Reviews, November 6, 2014    Clinical Article

12 Optimal glucocorticoid replacement in adrenal insufficiency Best Practice & Research Clinical Endocrinology & Metabolism, November 12, 2014    Review Article

13 The effect of nopal (Opuntia Ficus Indica) on postprandial blood glucose, incretins, and antioxidant activity in Mexican patients with type 2 diabetes after consumption of two different composition breakfasts Journal of the Academy of Nutrition and Dietetics, November 11, 2014    Clinical Article

14 Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies Full Text BMC Cardiovascular Disorders, November 17, 2014    Free full text    Evidence Based Medicine    Review Article    Clinical Article

15 Effects of low dose metformin in adolescents with type I diabetes mellitus: A randomized, double-blinded placebo-controlled study Full Text Pediatric Diabetes, April 7, 2014    Free full text    Clinical Article

16 Thyroid incidentalomas on PET imaging - Evaluation of management and clinical outcomes The Surgeon, August 11, 2014    Clinical Article

17 Prognostic factors for disease-specific survival in 108 patients with Hurthle cell thyroid carcinoma: A single-institution experience Full Text BMC Cancer, November 11, 2014    Free full text    Clinical Article

18 High protein weight loss diets in obese subjects with type 2 diabetes mellitus Nutrition, Metabolism & Cardiovascular Diseases, January 3, 2014    Clinical Article

19 Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials Full Text Drug Design, Development and Therapy, November 12, 2014    Free full text    Evidence Based Medicine    Review Article

20 Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: a potential role for glucose-dependent insulinotropic polypeptide? Diabetic Medicine, November 14, 2014    Clinical Article

Indexed Journals in Endocrinology: Endocrinology, Journal of Endocrinology, Clinical Endocrinology, Diabetesmore